BioGend Therapeutics Co., Ltd. (TPEX:6733)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
28.00
-0.05 (-0.18%)
May 13, 2025, 1:30 PM CST
-25.23%
Market Cap 3.48B
Revenue (ttm) 179.57M
Net Income (ttm) -138.80M
Shares Out 124.26M
EPS (ttm) -1.13
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 189,147
Average Volume 83,199
Open 28.35
Previous Close 28.05
Day's Range 27.70 - 28.35
52-Week Range 23.20 - 41.25
Beta 0.47
RSI 47.09
Earnings Date May 9, 2025

About BioGend Therapeutics

BioGend Therapeutics Co., Ltd. researches, develops, and sells orthopedic medical equipment and related products. It is developing BiG-001 and BiG-006, an osteoinductive bone graft substitute; and BiG-009, an autologous cartilage repair system. The company was incorporated in 2016 and is based in Taipei, Taiwan. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2016
Country Taiwan
Stock Exchange Taipei Exchange
Ticker Symbol 6733
Full Company Profile

Financial Performance

In 2024, BioGend Therapeutics's revenue was 167.65 million, an increase of 52.53% compared to the previous year's 109.91 million. Losses were -116.47 million, -25.49% less than in 2023.

Financial Statements

News

There is no news available yet.